A Large-Scale, Multi-Center Urine Biomarkers Identification of Coronary Heart Disease in TCM Syndrome Differentiation

2019 ◽  
Vol 18 (5) ◽  
pp. 1994-2003 ◽  
Author(s):  
Haonan Zhou ◽  
Lin Li ◽  
Huan Zhao ◽  
Yuming Wang ◽  
Jun Du ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Large Scale ◽  
Syndrome Differentiation ◽  
Urine Biomarkers ◽  
Tcm Syndrome

scholarly journals Study on TCM Syndrome Identification Modes of Coronary Heart Disease Based on Data Mining

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Qi Shi ◽  
Huihui Zhao ◽  
Jianxin Chen ◽  
Xueling Ma ◽  
Yi Yang ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
System Biology ◽  
Rapid Development ◽  
External Validation ◽  
Diagnostic Methods ◽  
Syndrome Differentiation ◽  
Biological Parameters ◽  
High Incidence ◽  
Tcm Syndrome

Coronary heart disease (CHD) is one of the most important types of heart disease because of its high incidence and high mortality. TCM has played an important role in the treatment of CHD. Syndrome differentiation based on information from traditional four diagnostic methods has met challenges and questions with the rapid development and wide application of system biology. In this paper, methods of complex network and CHAID decision tree were applied to identify the TCM core syndromes of patients with CHD, and to establish TCM syndrome identification modes of CHD based on biological parameters. At the same time, external validation modes were also constructed to confirm the identification modes.

The association of sleep quality and night sleep duration with coronary heart disease in a large-scale rural population

2021 ◽  
Vol 87 ◽  
pp. 233-240
Author(s):  
Bin Zhang ◽  
Yan Wang ◽  
Xiaotian Liu ◽  
Zhihan Zhai ◽  
Jiaqi Sun ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Sleep Quality ◽  
Sleep Duration ◽  
Rural Population ◽  
Large Scale ◽  
Night Sleep

scholarly journals Large-scale phenome-wide association study of PCSK9 loss-of-function variants demonstrates protection against ischemic stroke

2017 ◽  
Author(s):  
Abhiram S. Rao ◽  
Daniel Lindholm ◽  
Manuel A. Rivas ◽  
Joshua W. Knowles ◽  
Stephen B. Montgomery ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Ischemic Stroke ◽  
Protective Effect ◽  
Large Scale ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Genetic Associations ◽  
Loss Of Function

AbstractPCSK9 inhibitors are a potent new therapy for hypercholesterolemia and have been shown to decrease risk of coronary heart disease. Although short-term clinical trial results have not demonstrated major adverse effects, long-term data will not be available for some time. Genetic studies in large well-phenotyped biobanks offer a unique opportunity to predict drug effects and provide context for the evaluation of future clinical trial outcomes. We tested association of the PCSK9 loss-of-function variant rsll591147 (R46L) in a hypothesis-driven 11 phenotype set and a hypothesis-generating 278 phenotype set in 337,536 individuals of British ancestry in the United Kingdom Biobank (UKB), with independent discovery (n = 225K) and replication (n = 112K). In addition to the known association with lipid levels (OR 0.63) and coronary heart disease (OR 0.73), the T allele of rs11591147 showed a protective effect on ischemic stroke (OR 0.61, p = 0.002) but not hemorrhagic stroke in the hypothesis-driven screen. We did not observe an association with type 2 diabetes, cataracts, heart failure, atrial fibrillation, and cognitive dysfunction. In the phenome-wide screen, the variant was associated with a reduction in metabolic disorders, ischemic heart disease, coronary artery bypass graft operations, percutaneous coronary interventions and history of angina. A single variant analysis of UKB data using TreeWAS, a Bayesian analysis framework to study genetic associations leveraging phenotype correlations, also showed evidence of association with cerebral infarction and vascular occlusion. This result represents the first genetic evidence in a large cohort for the protective effect of PCSK9 inhibition on ischemic stroke, and corroborates exploratory evidence from clinical trials. PCSK9 inhibition was not associated with variables other than those related to low density lipoprotein cholesterol and atherosclerosis, suggesting that other effects are either small or absent.

scholarly journals Integrative Western and Chinese Medicine on Coronary Heart Disease: Where Is the Orientation?

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Siming Li ◽  
Hao Xu
Keyword(s):  
Coronary Heart Disease ◽  
Quality Control ◽  
Heart Disease ◽  
Integrative Medicine ◽  
Modern Medicine ◽  
Medicine Research ◽  
Prevention And Treatment ◽  
Fast Development ◽  
Original Innovation ◽  
Tcm Syndrome

Coronary heart disease (CHD) is the leading cause of death. As the main treatment of CHD, modern medicine has improved dramatically in recent years. Although researches of TCM and integrative medicine on CHD are witnessed encouraging progress in many respects, the role TCM playing in the prevention and treatment of CHD has been unprecedentedly challenged under such circumstance of the very fast development of modern medicine. In order to share mutual complementary advantages of TCM and western medicine, this review summarizes the relatively prominent researches of TCM and integrative medicine on CHD in recent years, and illuminates the issue of the orientation of the further research of integrative medicine on CHD, including (1) original innovation of TCM etiology and pathogenesis, (2) combination of disease and TCM syndrome, (3) biological basis of TCM syndrome of CHD, (4) clinical design and quality control of integrative medicine research, (5) herb-drug interaction, (6) difficulties and hot issues of modern medicine.

The therapeutic effect and mechanism of Qishen Yiqi dripping pills on cardiovascular and cerebrovascular diseases and diabetic complications

2021 ◽  
Vol 14 ◽  
Author(s):  
Chunlai Zhao ◽  
Wenjia Wang ◽  
Kaijing Yan ◽  
He Sun ◽  
Jihong Han ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Diabetic Nephropathy ◽  
Heart Disease ◽  
Ischemic Stroke ◽  
Diabetic Complications ◽  
Blood Stasis ◽  
Blood Stasis Syndrome ◽  
Syndrome Differentiation ◽  
Therapeutic Effects ◽  
The Common

: The alterations in vascular homeostasis is deeply involved in the development of numerous diseases, such as coronary heart disease, stroke, and diabetic complications. Changes in blood flow and endothelial permeability caused by vascular dysfunction are the common mechanisms for these three types of diseases. The disorders of glucose and lipid metabolism can result in changes of the energy production patterns in endothelium and surrounding cells which may consequently cause local energy metabolic disorders, oxidative stress and inflammatory responses. Traditional Chinese medicine (TCM) follows the principle of the “treatment by the syndrome differentiation”. TCM considers of that coronary heart disease, stroke and diabetes complications all as the type of “Qi deficiency and Blood stasis” syndrome, which mainly happens to the vascular system. Therefore, the common pathogenesis of these three types of diseases suggests the treatment strategy by TCM should be in a close manner and named as “treating different diseases by the same treatment”. Qishen Yiqi dripping pills is a modern Chinese herbal medicine which has been widely used for treatment of patients with coronary heart disease characterized as “Qi deficiency and blood stasis” in China. Recently, many clinical reports have demonstrated the potent therapeutic effects of Qishen Yiqi dripping pills on ischemic stroke and diabetic nephropathy. Based on these reports, we will summarize the clinical applications of Qishen Yiqi dripping pills on coronary heart disease, ischemic stroke and diabetic nephropathy, including the involved mechanisms with basic researches.

Drug Treatment in the Prevention of Coronary Artery Disease

1979 ◽  
Author(s):  
J.R.A. Mitchell
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Heart Disease ◽  
Clinical Trials ◽  
Heart Disease ◽  
Major Part ◽  
Large Scale ◽  
End Points ◽  
Pump Failure ◽  
Artery Disease

The disappointing performance of anticoagulants in the prophylaxis of coronary heart disease led to the realisation that components other than fibrin play a major part in the structure of arterial thrombi. Attention has therefore been focussed on the possible role of agents which modify platelet behaviour. Novel agents which alter thromboxane synthesis will not be available for large-scale clinical trials for some years, so the present trials are assessing the value of platelet-modifying agents which are already in use for other purposes. The implications of the Antura-Reinfarction study and the role of aspirin and persantin will be discussed.Attention will also be drawn to the importance of using valid end-points to assess potential anti-thrombotic regimes in coronary disease. The differential implications of using infarction, sudden death, pump failure, dysrhythmias and re-infarction as end-points in trials will be described.

scholarly journals LDL-C/HDL-C and carotid plaques in patients with coronary heart disease: A Chinese cohort study

2021 ◽  
Author(s):  
Zhu Li ◽  
Qi Cheng ◽  
Yijia Liu ◽  
Xufeng Cheng ◽  
Shuo Wang ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Large Scale ◽  
Healthy Lifestyle ◽  
Density Lipoprotein ◽  
Estimating Equation ◽  
Carotid Plaques ◽  
Cholesterol Ratio ◽  
Beneficial Effects ◽  
High Level

Abstract Background: Evidence of the association the low-/high-density lipoprotein cholesterol ratio (LDL-C/HDL-C) with the carotid plaques remains limited. The purpose of this study is to examine the association between LDL-C/HDL-C and carotid plaques of coronary heart disease (CHD), and to study what extent a healthy lifestyle reduces the risk of carotid plaques.Methods: In this large-scale and multi-center retrospective study, a total of 9,426 participants to explore the association between LDL-C/HDL-C and carotid plaques. No smoking and no drinking were considered healthy lifestyle. Generalised estimating equation models and conditional logistic regressions were used in statistical analyses.Results: In all the 9,426 participants, there were 6,989 (74.15%) patients having identified carotid plaques. High levels of LDL-C/HDL-C had a higher risk of carotid plaques than other lipid variables (OR:1.63; 95%CI:1.43-1.86). In stratified analyses by LDL-C/HDL-C triplet, participants in the LDL-C/HDL-C (＞3mmol/L) group had a higher risk of carotid plaques compared to other two groups. Compared with the unfavourable lifestyle, intermediate lifestyle or favourable lifestyle was associated with a significant 30% or 67% decrease in carotid plaques risk among patients with the LDL-C/HDL-C(＞3mmol/L) respectively. There were significantly additive and multiplicative interactions between lifestyle and LDL-C/HDL-C on carotid plaques.Conclusion: Our findings provide evidence that a high level of LDL-C/HDL-C can increase the risk of carotid plaques in patients with CHD. And adhering to a healthy lifestyle has additive beneficial effects on reducing the risk of carotid plaques.

Sign in / Sign up

Export Citation Format

Share Document